Detail

Chr	chr1
start	173863900
end	173868882
lncRNA name	GAS5
entrez id	60674
hgnc id	HGNC:16355
ensg id	ENSG00000234741
refseq id	NR_002578
methods	Microarray, qPCR, Western blot, RIP, luciferase reporter assay, Flow cytometry assay, etc.
regulated	down-regulation
function description	Collectively, our study demonstrates that GAS5 enhances the efficacy of tamoxifen in the treatment of breast cancer and could be a novel prognostic biomarker. Tamoxifen is a frequently used drug for hormonal therapy in patients with breast cancer, however, development of resistance to tamoxifen remains a serious clinical problem.Kaplan-Meier survival analysis was used to analyze the relationship between the expression of GAS5 and survival rate. P < 0.05 indicates a significant difference. Moreover, GAS5 increased sensitivity of breast cancer cells to tamoxifen by serving as a molecular sponge for miR-222, contributing to suppression of phosphatase and tensin homologs (PTEN) (one endogenous target of miR-222).
pubmed id	29969658
year	2018
title	Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer.
drug	V
circulating	X
survival	V